SEC Form 4 · accession 0001437749-18-001220
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard M. Altieri
Officer — Chief Financial Officer
Period of report
Jan 24, 2018
Accepted (ET)
Jan 26, 2018 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 24, 2018 | M | 152,330 | $0.18 | A | 202,965 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $0.18 | Jan 24, 2018 | M | 152,330 | D | — | Mar 31, 2022 | Ordinary Shares | 152,330 | 0 | D |
Explanation of responses
- F1Options became fully exercisable on March 31, 2016.